Teva Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 2/6
Teva Pharmaceutical Industries has a total shareholder equity of $6.4B and total debt of $19.0B, which brings its debt-to-equity ratio to 297.3%. Its total assets and total liabilities are $41.8B and $35.4B respectively. Teva Pharmaceutical Industries's EBIT is $3.7B making its interest coverage ratio 4. It has cash and short-term investments of $3.3B.
Key information
297.3%
Debt to equity ratio
US$18.98b
Debt
| Interest coverage ratio | 4x |
| Cash | US$3.32b |
| Equity | US$6.38b |
| Total liabilities | US$35.37b |
| Total assets | US$41.76b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: T1EV34's short term assets ($12.3B) do not cover its short term liabilities ($13.8B).
Long Term Liabilities: T1EV34's short term assets ($12.3B) do not cover its long term liabilities ($21.6B).
Debt to Equity History and Analysis
Debt Level: T1EV34's net debt to equity ratio (245.3%) is considered high.
Reducing Debt: T1EV34's debt to equity ratio has increased from 180.5% to 297.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable T1EV34 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: T1EV34 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.8% per year.